126.06MMarket Cap-4514P/E (TTM)
4.260High3.920Low427.31KVolume4.200Open4.220Pre Close1.71MTurnover2.68%Turnover RatioLossP/E (Static)31.91MShares20.71052wk High0.66P/B62.96MFloat Cap2.13052wk Low--Dividend TTM15.94MShs Float20.710Historical High--Div YieldTTM8.06%Amplitude2.130Historical Low4.004Avg Price1Lot Size
Sagimet Biosciences Stock Forum
Larger Image: tradingview.com...
$Sagimet Biosciences(SGMT.US)$
NEWS
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
In the fast-paced world of biotech investments, staying ahead of the curve is crucial for investors seeking substantial returns. Sagimet Biosciences (NASDAQ: SGMT), a company that has recently garnered significant attention from Leerink Partners, an esteemed investment firm, is one such entity that demands your immediate ...
$Leap Therapeutics(LPTX.US)$ Phase 2
$Vera Therapeutics(VERA.US)$ Phase 2b
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$Akero Therapeutics(AKRO.US)$ Phase 2b
$Spruce Biosciences(SPRB.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Annexon(ANNX.US)$ Phase 2a
$Roivant Sciences(ROIV.US)$...
SAN MATEO, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ("Sagimet") (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the commencement of an underwritten public offering of 9,000,000 shares of its Series A common st...
No comment yet